Prevalence of non-adherence to antihypertensive medication in Asia

Mahmood, Sajid ; Jalal, Zahraa; Hadi, Muhammad Abdul; Khan, Tahir Mehmood; Haque, Sayeed; Ullah Shah, Kifayat

DOI:

[10.1007/s11096-021-01236-z](https://doi.org/10.1007/s11096-021-01236-z)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Mahmood, S, Jalal, Z, Hadi, MA, Khan, TM, Haque, S & Ullah Shah, K 2021, 'Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis', *International Journal of Clinical Pharmacy*, vol. 43, no. 3, pp. 486-501. <https://doi.org/10.1007/s11096-021-01236-z>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Pharmacy. The final authenticated version is available online at: <https://doi.org/10.1007/s11096-021-01236-z>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Prevalence of non-adherence to antihypertensive medication in Asia: A Systematic Review and Meta-Analysis.

Author and Affiliation

Sajid Mahmood¹, Zahraa Jalal², Muhammad Abdul Hadi², Tahir Mehmood Khan⁴, M. Sayeed Haque³, Kifayat Ullah Shah¹

¹Department of Pharmacy, Quaid-e-Azam University, Islamabad 45320, Pakistan

²School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

³Institute of Applied Health Research, University of Birmingham, B15 2TT, UK

⁴Institute of Pharmaceutical Sciences, University of Veterinary and Animal Science (UVAS), Lahore, Pakistan

Mr. Sajid Mahmood (M. Phil)

Department of Pharmacy, Quaid-e-Azam University, Islamabad, 45320, Pakistan

Email address: sajidmahmood@bs.qau.edu.pk

Telephone number: +92-3364478696

Dr. Zahraa Jalal (PhD)

School of Pharmacy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

Email address: z.jalal@bham.ac.uk

Telephone number: +44 (0)121 414 4042

Dr. Muhammad Abdul Hadi (PhD)

School of Pharmacy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

Email address: m.a.hadi@bham.ac.uk

Dr. Tahir Mehmood Khan (PhD)

Institute of Pharmaceutical Sciences, University of Veterinary and Animal Science (UVAS), Lahore, Pakistan

Email address: tahir.khan@uvas.edu.pk

Telephone number: +923235568664

Dr. M. Sayeed Haque (PhD)

Institute of Applied Health Research, University of Birmingham, B15 2TT, UK

Email address: m.s.haque@bham.ac.uk

Corresponding Author:

Dr. Kifayat Ullah Shah (PhD)

Department of Pharmacy, Quaid-e-Azam University, Islamabad, 45320, Pakistan

Email address: kushah@qau.edu.pk

Telephone number: +92-3325542722

Prevalence of non-adherence to antihypertensive medication in Asia: A Systematic Review and Meta-Analysis.

Abstract

Background: Hypertension and its associated complications are one of the leading causes of morbidity and mortality in Asia. Racial disparities in terms of treatment outcomes among hypertension patients have been reported in literature with Asian patients resulting in poorer treatment outcomes. Non-adherence to antihypertensive therapy is frequently associated with poor treatment outcomes.

Aim of the Review: The aim of this review was to estimate the prevalence of non-adherence to antihypertensive medications among patients with hypertension residing in Asia.

Method: PubMed, Google Scholar, MEDLINE, Embase, Scopus, CINAHL and Cochrane library were searched for studies published between 2000 and 2019 involving hypertensive patients. Studies investigating the prevalence of medication non-adherence in Asian countries, rated either good or fair on National Institute of Health quality assessment tool and published in English language were included in our review. Data were extracted by one author and checked by another using a structured and pilot-tested data extraction sheet. A random-effects meta-analysis was performed using STATA version 14.3®.

Results: Sixty-Seven studies from 22 Asian countries including 2,532,582 hypertensive patients were included. Mean ($\pm$ SD) age of participants was 58($\pm$ 6) years. Overall, the estimated prevalence of non-adherence to antihypertensive medication in Asia was 48% (95% CI: 41-54, $P=0.001$). The rate of non-adherence was higher among females 49% (95% CI: 41-56, $P=0.001$) compared to males 47% (95% CI: 40-53, $P=0.001$). As per the region, the highest prevalence of non-adherence was found in South Asia 48% (95% 44-51, $P=0.877$) followed by East Asia 45% (31-59, $P=0.001$) and the Middle East 41 (95% 30-52, $P=0.001$). Similarly, higher rate of non-adherence was observed in low and lower middle-income countries i.e. 50% (95% CI: 47-54, $P=0.220$) as compare to upper-middle and high-income countries i.e. 37% (95% CI: 25-49, $P=0.001$) and 44% (29-59, $P=0.001$) respectively.

Conclusion:

The prevalence of non-adherence to antihypertensive medication is high in Asia. This may partly explain poor treatment outcomes and incidence of higher mortality rate in Asia frequently reported in the literature. There is a need to implement appropriate policies and clinical practices to improve medication adherence.

Impact on Practice:

- Non-adherence to antihypertensive therapy and barriers to medication adherence should be frequently discussed and during routine clinical consultation.
- Health policy makers should design and implement policies and promote good clinical practices to improve medication adherence taking into consideration local socioeconomic and cultural factors.
- More research is required to establish the effectiveness of interventions to improve medication adherence in low-and-middle-income countries.

Keywords: Compliance; Hypertension; Drug therapy; Asia, Systematic review,

Introduction:

Hypertension is a significant public health challenge globally especially in Asia, which is home to two-thirds of the world's population. Uncontrolled blood pressure may lead to stroke, coronary artery disease CAD, heart failure, renal insufficiency and blindness [1]. The prevalence of hypertension varies from 15% to 35% in different parts of Asia. In addition, hypertension control rate is poorer in Asia with China and India having hypertension control rates of only 8% and 6% respectively [2].

Adherence is the extent to which a patient takes his/her medicines as prescribed by a healthcare practitioner [3]. A meta-analysis found that adherence to prescribed antihypertensive therapy may reduce the risk for poor treatment outcomes by 26% and the odds of good treatment outcomes in adherent patients are three times higher than odds of good treatment outcomes in non-adherent patients [4]. For measurement of non-adherence both direct and indirect methods have been used in the literature to assess medication adherence. Direct methods (e.g. direct observation, assays to measure drug concentration in urine and blood) are considered as gold standard but are rarely used due to their high cost. Indirect methods (e.g. pill counting, questionnaires) are easier and more cost effective to apply for assessment of non-adherence [5].

Asia differs from other regions in the world in terms of ethnicity, culture, economy and systems of governance. The existing literature has reported that racial disparities exist in Asia with respect to prevalence, treatment and control of hypertension. The rate of blood pressure control in different parts of Asia varies between 10.6% to 41.4% [6]. Medication non-adherence is the main reason behind uncontrolled hypertension [7]. Low availability of electronic medical records, low health literacy, un-availability, unaffordability and lastly the scarcity of pharmacy refill records in Asian countries are the main factors that precludes the accurate measurement of medication adherence in these countries [8]. Hence it is important to estimate the 'burden' of non-adherence so that necessary policies and interventions to support clinical practice can be developed and implemented to improve medication adherence among hypertension patients in

Asia. Previous systematic reviews have evaluated factors associated with medication non-adherence and barriers to medication non-adherence among patients with hypertension and other cardiovascular disease conditions in different parts of the world [9, 10]. One systematic review estimated the overall global prevalence of non-adherence to antihypertensive medication to be 45.2% among hypertensive patients [9]. However, this systematic review only included studies using Morisky Medication Adherence Scale (MMAS-8) for assessing medication adherence and studies published between January 2009 and March 2016. Furthermore, authors did not perform any regional analysis to explore regional differences in medication adherence, if any. Therefore, these findings do not provide any exclusive information regarding the prevalence of non-adherence in the different regions of the world particularly in Asia. Given limitations of existing literature, a more comprehensive and up-to-date systematic review and meta-analysis was required to estimate the prevalence of non-adherence among hypertension patients. We focused this review to studies originated from Asia as hypertension and its associated morbidities are one of the leading causes of premature deaths in Asia. Furthermore, to the best of our knowledge, no such systematic review exists in the literature.

Aim of the review: The aim of this review was to estimate the prevalence of non-adherence to antihypertensive medications among hypertensive patients residing in Asia. This systematic review was designed to answer the following research questions:

Question#01: What is the overall prevalence of medication non-adherence to prescribed antihypertensive medication in Asia?

Question#02: Does the prevalence of non-adherence to prescribed antihypertensive medication differ across gender groups, geography, and income levels?

Method:

Preferred Reporting Item for Systematic Review and Meta-analysis (PRISMA) and Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed in undertaking and reporting this systematic review [11, 12]. The review was registered with PROSPERO, an international database of prospectively registered systematic reviews (ID number: CRD42018117403).

Inclusion and Exclusion Criteria: All cross-sectional studies conducted among patients with hypertension between 2000 and 2019 estimating the prevalence of non-adherence to medication therapy were included in this review. We did not include studies published prior to 2000 as including older studies would not truly represent the current status of non-adherence to anti-hypertensive therapy in Asia. Studies published in English language only were included in our review. Studies on Asian population residing outside Asia were not included in our review.

Only those studies that were rated either good or fair on National Institute of Health quality assessment tool [13] were included in our review. Quality assessment was done by one author and counterchecked by another author. In case of any disagreement, a third review author was consulted.

Study Search: A systematic search was carried out in PubMed, Google Scholar, MEDLINE, Embase, Scopus, CINAHL and Cochrane library. Some of the keywords used were: compliance, adherence, medication non-compliance, medication non-adherence, and antihypertensive therapy. These keywords were combined using Boolean operators as appropriate. Detailed search strategy has been provided in online supplementary file. Additionally, some relevant research papers were also retrieved through searching of reference lists, author contact and studies sent by colleagues through email.

Study selection and data extraction:

A reference management software Endnote® (version X5) was used for compilation of retrieved articles. The titles and abstracts were screened by one author for inclusion and when unsure, another author was consulted. Full-texts of relevant articles were downloaded and assessed for inclusion against the inclusion and exclusion criteria by one author and checked by another author. Disagreements were resolved through consensus. In instances where consensus had not reached between the two review authors, third review author was consulted. The data extraction sheet was created using Microsoft Excel®. The structured data extraction sheet was pilot-tested and changes were made, where necessary. The data extracted included: name of investigator, year of study, country of study, adherence scale used, population of study, gender percentage, mean age of participants, percentage of non-compliance to the prescribed antihypertensive therapy. The extracted data were grouped into different variables such as by country, geographic region and income level. Asian countries were categorised in different income level categories as defined by World Bank [14].

Data Quality Assessment:

National Institute of Health quality assessment tool [13] was used for quality assessment of all included studies. This tool consists of a fourteen-question standard quality checklist and is suitable for both observational cohort and cross-sectional studies. For each question, the

reviewer can choose from the three options, “Yes”, “No” and “Not applicable”, as appropriate. Based on these questions, the studies were categorized as of good, fair or poor quality by two reviewers independently. Differences in quality assessment were resolved through discussion among review authors. A third reviewer was consulted if differences were not resolved through discussion.

Statistical Analysis:

Meta-analysis was performed using STATA version 14.3®. Only clinical and statistical homogenous studies were combined using meta-analysis. Clinical homogeneity was assessed by review authors in terms of study population and methods used to assess medication adherence. I^2 with 95% confidence interval test was used to evaluate statistical heterogeneity of studies. I^2 value of less than 50% was used to indicate statistical homogeneity [15]. Analysis of proportions were carried out using random effect model to account for statistical heterogeneity. Furthermore, subgroup analyses were performed to address heterogeneity. Gender, income level and regional geography were used as grouping variables. In order to rule out the effect of different methods used for measuring the medication adherence on overall results of this study, sensitivity analyses were performed by separately analysing: the studies that used similar method/tool for measurement of medication adherence e.g. MMAS-8, MMAS-4; after removing the outlier values and studies that have either too large (sample size greater than 5,000) or too small sample size (sample size < 100); the studies with less frequently used adherence measurement tool/method i.e. less than two studies.

PRISMA 2009 Flow Diagram [11]

205

Identification

Screening

Eligibility

216

Included

220

221

222

223

Figure 1. PRISMA flow diagram

Results:

Search results: A total 1274 articles were identified from searching databases and additional four articles were retrieved from searching websites and reference lists. After deduplication, titles and abstracts of 926 studies were screened by one author (SM). Full-text of remaining one hundred and sixty-two were downloaded and reviewed for inclusion by one author and checked by another author. Finally, 66 articles met inclusion criteria. Reasons for exclusion of full-texts are given in PRISMA 2009 Flow Diagram (Figure 1).

Quality assessment of included studies: Over half of the studies 44/66 (66%) included in this review were rated good on the NIH Quality Assessment Tool and showed high internal validity. The remaining 22/66 (34%) studies rated good/fair.

Tools to Assess Medication Adherence: Morisky Medication Adherence Scale was the most commonly used instrument (34 studies) to assess medication adherence to anti-hypertensive drugs. Out of above referred 34 studies, 21 studies used “8-item Morisky Medication Adherence scale” (MMAS-8) [16-36], 11 studies used “4-item Morisky Medication Adherence scale” (MMAS-4) [37-47] and one study used “Morisky Green scale” (MGS) [48], for measurement of adherence. Twenty-four studies used “validated self-structured questionnaires” [49-72]. Pill count method [73, 74] and Hill-Bone Compliance Scale [75, 76] were used in two studies each. Brief Medication Questionnaire (BMQ) [77], “Therapeutic Adherence Scale for Hypertensive Patients” (TASHP) [78], “Cumulative Medication Adherence” (CMA) [79], Proportion of days covered PDC (≥80%) [80] and Hypertensive Adherence to Therapeutic Regimen Scale (HARTS) were used in one study each [81].

Characteristics of Studies Included: A total of 2,532,582 Asian subjects were included in 66 selected studies. Eight studies each from India [21, 52, 77, 45, 65, 34, 66, 48] and Saudi Arabia [24, 41, 59, 31, 68-71], six each from Bangladesh [53-57, 76] and China [16, 17, 38, 39, 63, 78], four each from Iran [26, 27, 43, 35], Pakistan [37, 58, 46, 22] and Japan [51, 64, 80, 72], three studies were from Jordan [44, 82, 75] and Indonesia [20, 32, 33] and Hong Kong [18, 19, 47], two studies each from United Arab Emirates [25, 42], South Korea [79, 73] Nepal [40, 67] Thailand [81, 74] and Iraq [61, 36] and one each from Malaysia [49], Oman [28], Myanmar [23], Turkey [62], Vietnam [50], Lebanon [30] and Palestine [29]. All included studies were cross sectional observational studies with sample size ranging from 45 to 2,455,193 subjects. Sixty-three studies collected their data through self-administered questionnaires, two studies used pill count method and one study each used proportion of days covered (PDC) and cumulative medication adherence (CMA) method for the measurement of medication adherence. Of 66 studies included in the review, 41 studies separately investigated non-adherence in males and females while remaining 25 studies only mentioned overall compliance in both male and female.

Key characteristics of the 2,532,582 subjects in the included 66 studies are given in Table-1. Majority of subjects were female (n= 1,462,746, 58% of total subjects included in the meta-analysis). The mean age ($\pm$ S.D) of participants was 58 ($\pm$ 6) years.

Non-adherence to antihypertensive medication: Overall, the meta-analysis estimated prevalence of medication non-adherence in Asia to be 48% (95%CI: 41-54, P=0.001) (Figure 2). A high statistical heterogeneity was observed in the analysis ($I^2 = 99.6\%$). The rate of non-adherence was marginally higher in females 49% (95%CI: 41-56, P=0.001) compared to males 47% (CI: 40-53, P=0.001) (see Supplementary Fig-1 and 2). As per the region, the highest prevalence of non-adherence to antihypertensive medication was found in South Asia 48% (95% CI:44-51, P=0.877) followed by East Asia 45% (95%CI:31-59, P=0.001) and the Middle East 41% (95% CI:30-52, P=0.001) (Supplementary Table-1) (Figure-3). However, a high statistical heterogeneity was observed in the analysis ($I^2 = 97.3\%$) Similarly, as per income level of the countries, comparatively higher prevalence of non-adherence was observed in low and lower middle-income countries i.e. 50% (95%CI:47-54, P=0.22) as compared to upper-middle and high-income countries i.e. 37% (95% CI:25-49, P=0.001) and 44% (95% CI: 29-59, P=0.001) respectively (Supplementary Table-2) (Figure-4). Similarly, a high statistical heterogeneity was observed in the analysis ($I^2=99.6$). The sensitivity analysis was undertaken on forty-five studies further stratified on the basis of research tool/method used. Among these forty-five studies, eighteen studies used MMAS-8, eight studies used MMAS-4 and remaining nineteen studies used validated structured questionnaires. The sensitivity analysis shown that no significant difference in level of non-adherence was observed from the overall pooled percentage when the studies using different methods/tools for measuring medication adherence were analysed separately after removing the outliers (Supplementary Fig-3-5). One study was automatically removed from meta-analysis by the software, treating it as an outlier because it had too large sample size i.e. 2,455,193 [79]. Adding a study with such a big sample size would have skewed the results and introduced bias in overall results.

Table-1: Characteristics of Studies Included in Systematic Review and Meta-analysis.

Sr#	Investigator	Year	Place of Study	Study Design	Scale Used	Sample Size	Gender Distribution		Gender Ratio Male: Female	Mean Age	Non-Adherence in Male % (CI 95%)	Non-Adherence in Female % (CI 95%)	Overall Non-Adherence % (CI 95%)
							Male	Female					
1.	Lee et al.	2012	China	Cross Sectional	MMAS-8	1114	465	649	41.7 :58.3	65.7 ± 11.1	38 (33-43)	32 (27-37)	35 (32-38)
2.	Ma et al.	2015	China	Cross Sectional	MMAS-4	1159	673	486	58.1 : 41.9	59.9 ± 10.06	N/A	N/A	79 (76-81)
3.	Yang et al.	2014	China	Cross Sectional	MMAS-4	745	345	400	46.3 : 53.7	56.4 ± 10.8	53 (48-58)	60 (55-65)	56 (53-60)
4.	Yue et al.	2014	China	Cross Sectional	MMAS-8	232	110	122	47.4 : 52.6	64.1 ± 11	N/A	N/A	26 (21-32)
5.	Pan et al.	2019	China	Cross Sectional	TASHP	488	242	246	49.59 : 50.41	N/A	79 (74-84)	66 (60-72)	73 (69-77)
6.	Zhang et al.	2018	China	Cross Sectional	Structured Questionnaire Form	1916	762	1154	39.8 : 60.2	72.2 ± 7.7	17 (14-19)	14 (12-16)	15 (13-16)
7.	Kang et al.	2014	Hong Kong	Cross Sectional.	MMAS-8	2445	1371	1074	43.9 : 56.1	65.5 ± 10.95	19 (17-21)	26 (23-29)	45 (43-47)
8.	Li et al.	2015	Hong Kong	Cross Sectional.	MMAS-8	2445	1120	1325	45.8 : 54.2	65.3 ± 11	N/A	N/A	46 (44-48)
9.	Suzanne et al.	2016	Hong Kong	Cross Sectional.	MMAS-4	195	40	151	20.5 : 79.5	76 ± 6.6	55 (40-70)	56 (48-64)	56 (49-63)
10.	Chui et al.	2017	South Korea	Cross Sectional.	Pill Count	1523	907	616	59.6 : 40.4	N/A	19 (17-22)	17 (14-19)	18 (16-20)
11.	Park et al.	2007	South Korea	Cross Sectional.	CMA (Cumulative Medication Adherence)	2,455,193	1,028,724	1,426,469	42 : 58	N/A	N/A	N/A	45 (45-45)
12.	Ramli et al.	2012	Malaysia	Cross Sectional	Structured Questionnaire Form	653	243	410	37.2 : 62.8	58 ± 9.8	44 (38-50)	51 (46-57)	47 (43-50)
13.	Athiyah et al.	2015	Indonesia	Cross Sectional	MMAS-8	204	55	149	27 : 73	N/A	N/A	N/A	66 (59-73)
14.	Rahmawati et al.	2017	Indonesia	Cross Sectional	MMAS-8	384	96	288	25 : 75	65.7 ± 10.3	N/A	N/A	89 (86-92)
15.	Violita et al.	2018	Indonesia	Cross Sectional	MMAS-8	134	41	93	30.6 : 69.4	57.6 ± N/A	N/A	N/A	58 (50-67)

16.	Pinprapapan et al.	2013	Thailand	Cross Sectional	Hypertensive Adherence to Therapeutic Regimen Scale (HARTS)	321	110	211	34.27 : 65.73	49 ± 5.79	N/A	N/A	51 (45-56)
17.	Woodham et al.	2018	Thailand	Cross Sectional	Pill Count	408	143	265	35 : 65	68 ± 5.92	82 (75-88)	89 (85-93)	87 (83-90)
18.	Nguyen et al.	2016-17	Vietnam	Cross Sectional	Structured Questionnaire Form	315	171	144	54.3 : 45.7	53.7 ± 6.95	55 (47-63)	44 (36-52)	50 (44-56)
19.	Saito et al.	2008	Japan	Cross Sectional	Structured Questionnaire Form	292	157	135	53.7 : 46.3	50.2 ± 6.6	43 (36-50)	N/A	64 (58-69)
20.	Suzuki et al.	2018	Japan	Cross Sectional	Structured Questionnaire Form	1372	953	419	69 : 31	67 ± 12	N/A	25 (21-29)	17 (15-19)
21.	Matsumura et al.	2018	Japan	Cross Sectional	Structured Questionnaire Form	687	342	323	51 : 49	65 ± 10.2	N/A	N/A	25 (22-28)
22.	Ishida et al.	2019	Japan	Cross Sectional	PDC- Proportion of days covered (≥80%)	47,891	27,293	20,598	57 : 43	70 ± 11.5	N/A	N/A	8.5 (8-9)
23.	Thomas et al.	2008-09	India	Cross Sectional	BMQ	608	310	298	51 : 49	58.40 ± N/A	N/A	N/A	50 (46-54)
24.	David et al.	2015	India	Cross Sectional	Morisky Green Scale	214	71	143	33 : 67	N/A	42 (32-51)	60 (51-69)	53 (46-60)
25.	Sutar et al.	2015-16	India (Goa)	Cross Sectional	MMAS-8	213	96	117	45 : 55	60.52 ± 5.4	N/A	N/A	5 (2-8)
26.	Bhandari et al.	2009	India	Cross Sectional	Structured Questionnaire Form	348	111	237	32 : 68	55.13 ± 12.4	N/A	N/A	27 (22-32)
27.	Balasubramanian et al.	2018	India	Cross Sectional	MMAS-4	189	93	96	49.2 : 50.8	65.12 ± 11.7	46 (36-56)	61 (51-71)	54 (47-61)
28.	Jayesh Shah et al.	2018	India	Cross Sectional	Structured Questionnaire Form	330	141	189	42.7 : 57.3	55.2 ± 12.6	62 (54-70)	60 (53-67)	61 (55-66)
29.	Jhag et al.	2018	India	Cross Sectional	MMAS-8	200	90	110	45 : 55	57.1 ± 12	29 (20-38)	28 (20-36)	29 (22-35)
30.	Gupta et al.	2019	India	Cross Sectional	Structured Questionnaire Form	100	33	67	33 : 67	55.6 ± 12.03	61 (44-77)	72 (61-82)	68 (59-77)
31.	Hossain et al.	2015	Bangladesh	Cross Sectional	Structured Questionnaire Form	146	103	43	70.5 : 29.5	N/A	49 (37-62)	35 (23-47)	45 (36-53)

32.	Karmokar et al.	2014	Bangladesh	Cross Sectional	Structured Questionnaire Form	350	251	99	71.6 : 28.4	50.49 ± 8.44	N/A	N/A	49 (44-54)
33.	Khanam et al.	2014	Bangladesh	Cross Sectional	Structured Questionnaire Form	1068	417	651	39 : 61	44.6 ± 15.8	29 (24-35)	24 (19-30)	26 (24-29)
34.	Hussain et al.	2006	Bangladesh	Cross Sectional	Structured Questionnaire Form	120	83	37	69.2 : 30.8	57 ± 11	N/A	N/A	85 (77-91)
35.	Ekram et al.	2006-07	Bangladesh	Cross Sectional	Structured Questionnaire Form	300	177	123	59 : 41	52 ± 11	N/A	N/A	87 (83-91)
36.	Ullah et al.	2019	Bangladesh	Cross Sectional	Hill-Bone Scale	144	66	78	46 : 54	56.1 ± N/A	58 (46-69)	51 (40-62)	55 (47-63)
37.	Ahmed et al.	2007	Pakistan	Cross Sectional	Structured Questionnaire Form	89	22	67	25 : 75	56 .1± 12.5	N/A	N/A	52 (41-62)
38.	Hashmi et al.	2005-06	Pakistan	Cross Sectional	MMAS-4	438	199	239	45.4 :54.6	54 ± 10	23 (15-32)	24 (16-33)	23 (19-28)
39.	Ali et al.	2012	Pakistan	Cross Sectional	MMAS-8	32	18	14	56 : 44	56 ± N/A	77 (56-91)	86 (75-96)	81 (64-93)
40.	Arshad et al.	2015	Pakistan	Cross Sectional	MMAS-4	106	53	53	50 : 50	58.8 ± 12.26	49 (36-63)	51 (37-64)	29 (21-38)
41.	Bhandari et al.	2009-10	Nepal	Cross Sectional	MMAS-4	154	N/A	N/A	N/A	N/A	31 (21-41)	54 (41-66)	44 (36-52)
42.	Shreshta et al.	2018	Nepal	Cross Sectional	Structured Questionnaire Form	260	132	128	51 : 49	N/A	53 (45-62)	43 (34-52)	48 (42-54)
43.	Han et al.	2015	Myanmar	Cross Sectional	MMAS-8	216	89	127	41.2 : 58.8	52.8 ± 12.5	46 (36-56)	54 (44-64)	49 (42-56)
44.	Elbur et al.	2013	Saudi Arabia	Cross Sectional	MMAS-4	144	N/A	N/A	N/A	N/A	N/A	N/A	65 (57-63)
45.	Al-Sowielem et al.	2001	Saudi Arabia.	Cross Sectional	Structured Questionnaire Form	190	51	139	27 : 73	50 ± 11.7	69 (61-77)	65 (57-73)	66 (59-73)
46.	Shaik et al.	2013-14	Saudi Arabia	Cross Sectional	MMAS-8	282	111	171	39.4 : 60.6	52 ± 12.05	56 (48-64)	54 (46-62)	55 (49-61)
47.	Khayyat et al.	2016	Saudi Arabia	Cross Sectional	MMAS-8	204	58	146	28.4 : 71.6	59 ± 12.2	40 (27-53)	59 (51-66)	54 (46-62)
48.	Alkhamis et al.	2019	Saudi Arabia	Cross Sectional	Structured Questionnaire Form	372	231	141	62 : 38	53 ± 12.4	52 (46-58)	42 (34-50)	49 (44-54)

49.	Alotayfi et al.	2018	Saudi Arabia	Cross Sectional	Structured Questionnaire Form	267	116	160	42 : 58	N/A	71 (62-79)	65 (58-72)	67 (62-73)
50.	Abdelhalim et al.	2019	Saudi Arabia	Cross Sectional	Structured Questionnaire Form	402	198	204	49 : 51	54.09 ± 10.7	80 (75-86)	41 (34-47)	60 (56-65)
51.	Alqarni et al.	2018	Saudi Arabia	Cross Sectional	Structured Questionnaire Form	108	30	78	27.8 : 72.2	N/A	58 (47-69)	90 (79-101)	67 (58-76)
52.	Bader et al.	2012-13	UAE	Cross Sectional	MMAS-4	250	134	116	53.6 : 46.4	44 ± 5.6	53 (43-62)	37 (28-46)	46 (39-52)
53.	Fahey et al.	2005-06	UAE	Cross Sectional	MMAS-8	203	102	101	50 : 50	52 ± N/A	N/A	N/A	48 (41-55)
54.	Sadat et al.	2014	Iran	Cross Sectional	MMAS-8	280	118	162	42.1 : 57.9	60.3 ± 10	N/A	N/A	51 (45-57)
55.	Behnood-Rod et al.	2014	Iran	Cross Sectional	MMAS-8	280	118	162	42.1 : 57.9	60 ± 10	50 (42-59)	50 (41-59)	50 (44-56)
56.	Kamran et al.	2013	Iran	Cross Sectional	MMAS-4	671	169	501	25.18 : 74.8	N/A	77 (74-81)	75 (71-79)	76 (72-79)
57.	Sadeghi et al.	2018	Iran	Cross Sectional	MMAS-8	600	181	419	30 : 70	56.44 ± 12.3	N/A	N/A	51 (47-55)
58.	Laila et al.	2016	Jordan	Cross Sectional	Hill-Bone	192	65	127	34 : 66	52.8 ± N/A	N/A	N/A	8 (4-12)
59.	Al-Jbour et al.	2013	Jordan	Cross Sectional	MMAS-4	273	84	189	30.8 : 69.2	69 ± 2.3	N/A	N/A	13 (9-17)
60.	Goussouset et al.	2015	Jordan	Cross Sectional	Structured Questionnaire Form	471	216	255	45.9 : 54.1	59 ± 11.18	26 (19-35)	23 (15-31)	24 (20-28)
61.	Al-banna et al.	2008	Iraq	Cross Sectional	Structured Questionnaire Form	418	127	291	30.4 : 69.6	N/A	14 (8-20)	12 (5-19)	12 (9-15)
62.	Ismael et al.	2018	Iraq	Cross Sectional	MMAS-8	335	145	190	43.3 : 56.7	58.69 ± 11.9	39 (31-47)	62 (55-79)	46 (41-51)
63.	Al-Noumani et al.	2015	Oman	Cross Sectional	MMAS-8	45	16	29	35.6 : 64.4	52 ± 14.6	N/A	N/A	51 (36-66)
64.	Al-Ramahi et al.	2011	Palestine	Cross Sectional	MMAS-8	450	197	253	43.8 : 56.2	59 ± 12.2	54 (48-60)	54 (48-60)	54 (49-59)
65.	Mohammad et al.	2015	Lebanon	Cross Sectional	Structured Questionnaire Form	210	85	125	40.5 : 59.5	59.3 ± 12.2	N/A	N/A	22 (17-29)
66.	Cingil et al.	2005	Turkey	Cross Sectional	Structured Questionnaire Form	194	50	144	26 : 74	N/A	13 (3-21)	35 (27-42)	29 (23-36)

293 Abbreviations: MMAS-8: 8-items Morisky Medication Adherence Scale, MMAS-4: 4-items Morisky Medication Adherence Scale, TASHP: Therapeutic Adherence Scale for Hypertensive Patients, CMA:
294 Cumulative Medication Adherence, HARTS: Hypertensive Adherence to Therapeutic Regimen Scale, PDC: Proportion of days covered ($\geq 80\%$), BMQ: Brief Medication Questionnaire, N/A: Not Available.

295

296

297

298

Figure 2: Meta-analysis of non-adherence among hypertensive patients (66 studies)

Figure 3: Meta-analysis of non-adherence in different regions of Asia (22 countries)

Figure 4: Meta-analysis of non-adherence in different income countries of Asia (22 countries)

Discussion:

The purpose of this review was to estimate the prevalence of non-adherence to antihypertensive medications in Asia. The findings of our review found that almost half of the studied participants across 22 countries in Asia were non-adherent to antihypertensive medications. This may explain poor treatment outcomes and increased financial burden on healthcare systems due to the complications associated with hypertension [83].

The prevalence of non-adherence to antihypertensives reported in our review [48% (41-54 P=0.001)] is higher than that reported in Asia in an earlier meta-analysis by Abegaz et al. [43.5% (35-53, P>0.001)]. However, this study included only seven Asian countries mostly from East Asia [9]. The sensitivity analysis found no significant difference in the rate of non-adherence among studies that used different methods/tools to measure non-adherence. Similarly, the outliers and sample size also had very little effect on overall results.

We stratified results based on gender and found a statistically non-significant higher prevalence of non-adherence among females compared to male hypertensive patients. Mixed results have been reported in the literature terms of gender differences related to medication adherence. Some studies from Asia found female patients to be more adherent to antihypertensive treatment than their male counterparts [84, 85, 16]. On the contrary, there are Asian studies that found male patients more adherent to their prescribed anti-hypertensive medication than female patients [31, 24].

A number of studies conducted in Asia have explored the barriers associated with medication adherence in hypertensive patients. These identified barriers can be categorized into patient related factors, socioeconomic factors, Therapy related factors and disease related factors [86, 87]. The patient related factors cited in different studies include forgetfulness, language barriers and patient preferences, patient knowledge, disruption of patient routine and family support. The socioeconomic factors identified by different studies include unaffordability, unemployment, low-income. The therapy related factors include side effects and dosage regimen frequency. Healthcare system related factors include lack of insurance, longer wait times to get hospital appointment, poor communication between healthcare provider and patient and lack of automatic prescription renewal. Similarly, condition related barriers cited in different Asian studies include absence of symptoms, presence of disease related complication and previous hospitalization due to the disease [8, 7, 38]. However, among women, dissatisfaction with communication with healthcare providers and depressive symptoms are the most important causes of medication non-adherence [63]. Clinicians should take into consideration gender differences and be aware that reasons may vary between patients [88]. Therefore, interventions to improve adherence should be tailored to the needs of patients in order to have a positive effect [89].

We found a higher rate of non-adherence to antihypertensive medications in low and lower middle-income countries i.e. 50% (47-54, $P=0.220$) as compared to upper-middle and high-income countries i.e. 37% (25-49, $P=0.001$) and 44% (29-59, $P=0.001$) respectively. This difference may be due to higher level of disease awareness and better healthcare system across higher-middle and high-income countries compared to lower-middle and low-income countries. Furthermore, factors such as lack of suitable healthcare resources, inequality in terms of access to healthcare facilities and lack of affordability all play a role in augmenting the problem [90, 10] in low- and middle-income countries. Subsequently, the burden and incidence of hypertension associated complications is higher in low- and middle-income countries compared with developed countries [61, 65].

The regional factors such as ethnicity, culture, economic conditions and healthcare systems should be kept in mind while designing any intervention aiming at improving medication adherence among patients with hypertension. A number of countries in Asia have limited healthcare resources, hence there is a need to develop interventions that are cost effective and easily implementable. Any interventions targeting at improving health awareness could be useful in improving medication adherence. The healthcare providers such as physicians, pharmacists and community health workers could play their role in educating the patients regarding the benefits of taking their medications regularly [8, 91, 92]. Better communication between patient and healthcare providers has shown a positive effect on medication adherence. Several regions in Asia have high cell phone density, hence using the communication technologies such as SMS reminders, mobile applications and electronic medication reconciliation could help improving medication adherence [93-95]. Motivational interviewing has also shown positive results in improving medication adherence [96]. Behavioural interventions such as memory aids and synchronizing therapeutic activities with daily routine for example taking medication after prayer or before shower could be useful in improving medication adherence [97, 98]. Lastly the Unaffordability and unavailability of anti-hypertensive medications also contributes to the medication non-adherence, hence any intervention targeting these issues could be helpful in improving medication adherence [7].

Limitations:

A high level of heterogeneity was observed in the studies included in the meta-analysis. This high proportion of heterogeneity may be due to differences in patient characteristics, cultural variations, demographic variations and study methodologies. Furthermore, a questionnaire that is successfully used to measure non-adherence in one country does not always mean that it can measure adherence in another country with the same degree of accuracy. This could be due to cultural and linguistic differences in different parts of the world. We only included studies published in English language only which might have resulted in missing some valuable articles

published in languages other than English. Furthermore, we only searched for peer-reviewed articles but not grey literature and conference abstracts and used minimum quality threshold for studies to be included which might have introduced publication bias. Despite our best efforts to include each and every country in our study we could not find any study from Afghanistan, Maldives, Uzbekistan, Tajikistan and Turkmenistan. However, the countries included in our review represent more than 90% of the population of Asia.

Conclusion:

Overall non-adherence to antihypertensive medications is high in Asian countries. Non-adherence to prescribed antihypertensive therapy is slightly higher in South Asia when compared to East Asia and the Middle East. Similarly, the rate of non-adherence to prescribed antihypertensive medications was higher in low- and lower middle-income countries as compared to upper-middle and high-income countries. Interventions aimed at improving adherence in Asian countries should consider gender differences. Prevention policies need to be in place for Asian countries to raise awareness of hypertension and reduce its burden.

Acknowledgement: None

Funding: None

Conflicts of Interest: The authors declare that they have no conflict of interest.

References:

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*. 2012;380(9859):2224-60.
2. Naseem A, Fatima A, Razzaque G, Haque N, Riaz S, Tahir M. Assessment of the Level of Disease State Knowledge among Hypertensive Patients in Public Sector Tertiary Care Hospitals of Quetta, Pakistan. *Imperial Journal of Interdisciplinary Research*. 2017;3(3).
3. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med*. 2005;353(5):487-97.
4. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes a meta-analysis. *Med care*. 2002;43(3):794-811.
5. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. *Clin Ther*. 1999;21(6):1074-90.
6. Jin C-N, Yu C-M, Sun J-P, Fang F, Wen Y-N, Liu M et al. The healthcare burden of hypertension in Asia. *Heart Asia*. 2013;5(1):238-43.
7. Mahmood S, Jalal Z, Hadi MA, Orooj H, Shah KU. Non-Adherence to Prescribed Antihypertensives in Primary, Secondary and Tertiary Healthcare Settings in Islamabad, Pakistan: A Cross-Sectional Study. *Patient preference adherence*. 2020;14(73):1-12.
8. Akeroyd JM, Chan WJ, Kamal AK, Palaniappan L, Virani SS. Adherence to cardiovascular medications in the South Asian population: a systematic review of current evidence and future directions. *World J Cardiol*. 2015;7(12):938-47.

9. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. *Medicine*. 2017;96(4):1-9.
10. Nielsen JØ, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low-and middle-income countries: a systematic review and meta-analysis of 92443 subjects. *Journal of human hypertension*. 2017;31(1):14.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264-9.
12. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007;147(8):573-7.
13. Health Nlo. Quality assessment tool for observational cohort and cross-sectional studies. National Heart, Lung, and Blood Institute Available from: www.nhlbi.nih.gov/health-pro/guidelines/indevelop/cardiovascular-risk-reduction/tools/cohort[Accessed November 5, 2015]. 2014.
14. World-Bank. World Bank Countries Classification by Income Level. 2019. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups#:~:text=For%20the%20current%202021%20fiscal,those%20with%20a%20GNI%20per>. Accessed 15/12/2019 2019.
15. Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org. 2011.
16. Lee GK, Wang HH, Liu KQ, Cheung Y, Morisky DE, Wong MC. Determinants of medication adherence to antihypertensive medications among a Chinese population using Morisky Medication Adherence Scale. *PLoS One*. 2013;8(4):96-104.
17. Yue Z, Li C, Weilin Q, Bin W. Application of the health belief model to improve the understanding of antihypertensive medication adherence among Chinese patients. *Patient Educ Couns*. 2015;98(5):669-73.
18. Kang CD, Tsang PP, Li WT, Wang HH, Liu KQ, Griffiths SM et al. Determinants of medication adherence and blood pressure control among hypertensive patients in Hong Kong: a cross-sectional study. *Int J Cardiol*. 2015;182(23):250-7.
19. Li YT, Wang HH, Liu KQ, Lee GK, Chan WM, Griffiths SM et al. Medication adherence and blood pressure control among hypertensive patients with coexisting long-term conditions in primary care settings: A cross-sectional analysis. *Medicine (Baltimore)*. 2016;95(20).
20. Athiyah U, Machfud AR, Aldila F, Yunita L, Ananda MR, Rizka NE. Measurement of Patient Adherence to the Use of Ntihypertensive Drugs by Mmas-8 nnd Pill Count in 5 Primary Health Centres of Surabaya/Antihipertansif ilaçlara hasta uyuncunun surabaya'nin 5 temel saglik merkezinde mmas-8 ve pill count yöntemleriyle belirlenmesi. *FABAD JPharm Sci*. 2013;38(2):91-7.
21. Sutar PA, Shah HK. A study of adherence pattern toward antihypertensive therapy (antihypertensive drugs, dietary habits, and physical activity) and certain factors affecting it. *Int J Med Sci Public Health*. 2017;6(3):463-72.
22. Saleem F, Hassali AA, Shafie AA. Hypertension in Pakistan: time to take some serious action. *Br J Gen Pract*. 2010;60(575):449-50.
23. Han WP, Hong SA, Tiraphat S. Factors related to medication adherence among essential hypertensive patients in tertiary hospitals in Yangon, Myanmar. *Indian J Public Health Res Dev*. 2015;13(2):57-70.
24. Shaik SA, Alsuwailam A, Alhargan A, Alsuwailam A, Alshiha D, AlGhalib H et al. Medications adherence level and its associated factors among hypertensive patients at a major referral hospital, in Riyadh, KSA. *Asian J Med Sci*. 2016;7(4):24-30.
25. Fahey M, Abdulmajeed A, Sabra K. Measurement of adherence to anti-hypertensive medication as perceived by doctors and patients. *Qatar Med J*. 2006;15(1):44-8.

26. Saadat Z, Nikdoust F, Aerab-Sheibani H, Bahremand M, Shobeiri E, Saadat H et al. Adherence to antihypertensives in patients with comorbid condition. *Nephrourol Mon.* 2015;7(4).

27. Behnood-Rod A, Rabbanifar O, Pourzargar P, Rai A, Saadat Z, Saadat H et al. Adherence to antihypertensive medications in Iranian patients. *Int J Hypertens.* 2016;2016(1):1-7.

28. Al-Noumani H, Wu J-R, Barksdale D, Knafl G, AlKhasawneh E, Sherwood G. Health Beliefs and Medication Adherence in Omanis With Hypertension. *J Cardiovasc Nurs.* 2018;33(6):518-26.

29. Al-Ramahi R. Adherence to medications and associated factors: A cross-sectional study among Palestinian hypertensive patients. *J Epidemiol Glob Health.* 2015;5(2):125-32.

30. Yassine M, Al-Hajje A, Awada S, Rachidi S, Zein S, Bawab W et al. Evaluation of medication adherence in Lebanese hypertensive patients. *Clin Epidemiol Glob Health.* 2016;6(3):157-67.

31. Khayyat SM, Khayyat SMS, Alhazmi RSH, Mohamed MM, Hadi MA. Predictors of medication adherence and blood pressure control among Saudi hypertensive patients attending primary care clinics: a cross-sectional study. *PLoS One.* 2017;12(1):255-67.

32. Rahmawati R, Bajorek B. Factors affecting self-reported medication adherence and hypertension knowledge: A cross-sectional study in rural villages, Yogyakarta Province, Indonesia. *Chronic Illn.* 2018;14(3):212-27.

33. Violita F, Thaha ILM, Dwinata I, Susanna D. Factors Associated with Medication Adherence of Patients with Hypertension in Segeri's HealthCenter. *KnE life sci.* 2018;4(4):173-80.

34. Jhaj R, Gour PR, Kumari S, Sharma S. Association between medication adherence and blood pressure control in urban hypertensive patients in central India. *Int J Non-Commun Dis.* 2018;3(1):19-25.

35. Sadeghi N. Study of adherence to treatment & its related factors in hypertensive patients referring to erman health centers in 1396: School of Medicine, Kerman University of Medical Sciences, Kerman, Iran; 2018.

36. Ismael Z. Compliance of Hypertensive Patients to Medication in AL-Imam AL-Hussein medical City-Karbala-2018. *J Kerbala Med.* 2019;11(2):36-43.

37. Hashmi SK, Afridi MB, Abbas K, Sajwani RA, Saleheen D, Frossard PM et al. Factors associated with adherence to anti-hypertensive treatment in Pakistan. *PLoS One.* 2007;2(3):1-8.

38. Ma C. A cross-sectional survey of medication adherence and associated factors for rural patients with hypertension. *Appl Nurs Res.* 2016;31(6):94-9.

39. Yang S, He C, Zhang X, Sun K, Wu S, Sun X et al. Determinants of antihypertensive adherence among patients in Beijing: application of the health belief model. *Patient Educ Couns.* 2016;99(11):1894-900.

40. Bhandari B, Bhattarai M, Bhandari M, Ghimire A, Pokharel P, Morisky D. Adherence to antihypertensive medications: population based follow up in Eastern Nepal. *J Nepal Health Res Council.* 2015;13(38-42).

41. Elbur AI. Level of adherence to lifestyle changes and medications among male hypertensive patients in two hospitals in Taif; Kingdom of Saudi Arabia. *Int J Pharm Pharm Sci.* 2015;7(4):168-72.

42. Bader R, Koprulu F, Hassan N, Ali A, Elnour A. Predictors of adherence to antihypertensive medication in northern United Arab Emirates. *East Mediterr health j.* 2015;21(5):309-18.

43. Kamran A, Ahari SS, Biria M, Malpour A, Heydari H. Determinants of patient's adherence to hypertension medications: application of health belief model among rural patients. *Ann Med Health Sci Res.* 2014;4(6):922-7.

44. Kamel BA-JAA, Barhoom H. Knowledge about Hypertension and Antihypertensive Medication Compliance in a Jordanian Community Sample. *J Interprof Educ Pract.* 4(24):2222-1735.

45. Balasubramanian A, Nair SS, Rakesh P, Leelamoni K. Adherence to treatment among hypertensives of rural Kerala, India. *J Family Med Prim Care.* 2018;7(1):64-9.

46. Arshad AR. Frequency of poor adherence to antihypertensive treatment and an analysis of clinico-demographic correlates. *J Coll Physicians Surg Pak.* 2015;25(12):911-3.

512 47. Lo SH, Chau JP, Woo J, Thompson DR, Choi KC. Adherence to antihypertensive medication in older
513 adults with hypertension. *J Cardiovasc Nurs*. 2016;31(4):296-303.

514 48. David R, Singh S, Isaac R. A study of treatment adherence and control status of diagnosed hypertensive
515 patients in a rural community, Ludhiana. *Int J Res Med Sci*. 3(2):247-51.

516 49. Ramli A, Ahmad NS, Paraidathathu T. Medication adherence among hypertensive patients of primary
517 health clinics in Malaysia. *Patient preference adherence*. 2012;6(3):613.

518 50. Schuiling-Veninga CC, Nguyen TBY, Vu T-H, Wright EP, Postma MJ. Adherence to hypertension
519 medication: Quantitative and qualitative investigations in a rural Northern Vietnamese community. *PLoS*
520 *One*. 2017;12(2):1-13.

521 51. Saito I, Nomura M, Hirose H, Kawabe H. Use of home blood pressure monitoring and exercise, diet
522 and medication compliance in Japan. *Clin Exp Hypertens*. 2010;32(4):210-3.

523 52. Bhandari S, Sarma PS, Thankappan KR. Adherence to antihypertensive treatment and its determinants
524 among urban slum dwellers in Kolkata, India. *Asia-Pac J Public Health*. 2015;27(2):NP74-NP84.

525 53. Hossain SZ, Islam MR, Biswas S, Biswas PK, Hossain MZ, Islam N et al. Pattern of compliance to anti-
526 hypertensive medications in hypertensive patients in a tertiary care hospital in Bangladesh. *J Dhaka Med*
527 *Coll*. 2015;24(1):62-6.

528 54. Karmoker KK, Dutta B, Khalil MI, Rashid MB, Alam MA, Islam MJ et al. Treatment compliance of
529 Hypertensive Patients. *J Cardiovasc*. 2016;8(2):110-4.

530 55. Khanam MA, Lindeboom W, Koehlmoos TLP, Alam DS, Niessen L, Milton AH. Hypertension: adherence
531 to treatment in rural Bangladesh—findings from a population-based study. *Glob Health Action*.
532 2014;7(1):25028.

533 56. Hussain S, Boonshuyar C, Ekram A. Non-adherence to antihypertensive treatment in essential
534 hypertensive patients in Rajshahi, Bangladesh. *Anwer Khan Mod Med Coll J*. 2011;2(1):9-14.

535 57. Ekram AS, Hussain SM, Boonshuyar C. Preliminary report on non-adherence to antihypertensive
536 treatment in essential hypertensive patients: a community based survey. *J Teach Assoc*. 2008;21(2):112-
537 7.

538 58. Ahmed N, Abdul Khaliq M, Shah SH, Anwar W. Compliance to antihypertensive drugs, salt restriction,
539 exercise and control of systemic hypertension in hypertensive patients at Abbottabad. *J Ayub Med Coll*
540 *Abbottabad*. 2008;20(2):66-9.

541 59. Al Sowieleh L, El Zubier A. Compliance and knowledge of hypertensive patients attending PHC centres
542 in Al-Khobar, Saudi Arabia. *East Mediterr health j*. 1998;4(2):301-7.

543 60. Goussous LS, Halasah NA, Halasa M. Non-Compliance to Antihypertensive Treatment among Patients
544 Attending Prince Zaid Military Hospital. *Fam Med*. 2015;13(1):15-9.

545 61. Al-banna HI, Moha SMS. Compliance to Antihypertensive Treatment and Causes of Partial or Poor
546 Compliance in Patients Attending Ali-Kamal Consultation Center in Suliamania. *Zanco J Med Sci*.
547 2010;14(1):78-84.

548 62. Cingil D, Delen S, Aksuoğlu A. Evaluation of compliance and level of knowledge of patients with
549 hypertension living in Karaman city center, Turkey. *Turk Kardiyol Dern Ars*. 2009;37(8):551-6.

550 63. Zhang Y, Li X, Mao L, Zhang M, Li K, Zheng Y et al. Factors affecting medication adherence in
551 community-managed patients with hypertension based on the principal component analysis: evidence
552 from Xinjiang, China. *Patient preference adherence*. 2018;12(1):803-15.

553 64. Suzuki T, Shiga T, Omori H, Tatsumi F, Nishimura K, Hagiwara N. Self-reported non-adherence to
554 medication in Japanese patients with cardiovascular diseases. *J Cardiovasc Pharmacol*. 2018;18(4):311-6.

555 65. Shah AJ, Singh V, Patil SP, Gadkari MR, Ramchandani V, Doshi KJ. Factors affecting compliance to
556 antihypertensive treatment among adults in a tertiary care hospital in Mumbai. *Indian J Community Med*.
557 2018;43(1):53-5.

558 66. Gupta SK. TREATMENT ADHERENCE AMONG PEOPLE LIVING WITH HYPERTENSION IN PERIURBAN
559 COMMUNITY OF CHANDIGARH: A CROSS SECTIONAL STUDY. *Paripex Indian J Res*. 2019;8(9):88-9.

67. Shrestha B, Ferdoush Z, Rabbi F, Hossain A. Adherence to medications among Nepali hypertensive population: a hospital-based cross-sectional study. *Biomed Res Int*. 2018;3(1):1-4.
68. Alkhamis AM, Alsalman AJ, Al Khamis M, Alkhamis A, Alotaibi NM. Prevalence of Nonadherence to Antihypertensive Medications among Adults Attending Primary Healthcare Clinics in Al-Hasa Region: A Cross-Sectional Study. *Dr Sulaiman Al Habib Medical Journal*. 2019;1(2):26-43.
69. Alotayfi MJY, Alsohaimi SA, AL-Qadi BK, Kamil SM, Aththi AJH, Alhazmi GAA et al. Poor Compliance to Anti-Hypertensive Drugs in Saudi Arabia. *Egypt J Hosp Med*. 2018;73(5):6696-701.
70. Abdelhalim HN, Zahrani AI, Shuaibi AM. Factors affecting treatment compliance of patients on antihypertensive therapy at National Guard Health Affairs (NGHA) Dammam Primary Health Care Clinics (PHCC). *J Family Community Med*. 2019;26(3):168-72.
71. Alqarni AM, Hammad AS, Alhejaili MA, Alatawi AA, Alrashedi MH, Alenezi MF et al. Assessment of Adherence to Hypertension Medications and Awareness of Hypertension Medications among People with Hypertension in Tabuk. *Egypt J Hosp Med*. 2018;70(8):1365-70.
72. Matsumura S, Watanabe K, Fukuhara S. The association between physician's affiliation and patients' adherence to their antihypertensive medication and pharmaceutical knowledge. *J Gen Fam Med*. 2019;20(1):19-24.
73. Choi HY, Im Jung Oh JAL, Lim J, Kim YS, Jeon T-H, Cheong Y-S et al. Korean J Fam Med. Korean journal of family medicine. 2018;39(6):325-32.
74. Woodham N, Taneepanichskul S, Somrongthong R, Auamkul N. Medication adherence and associated factors among elderly hypertension patients with uncontrolled blood pressure in rural area, Northeast Thailand. *J Health Res*. 2018;32(6):449-58.
75. Al-daken LI, Eshah NF. Self-reported adherence to therapeutic regimens among patients with hypertension. *Clin Exp Hypertens*. 2017;39(3):264-70.
76. Ullah M, Saha SK, Rahman MT, Karim MA, Ahmed R. Nonadherence to Drugs among the Hypertensive Patients in Outpatient Department of a Secondary Hospital of Bangladesh. *JCardiovasc*. 2019;11(2):105-13.
77. Dennis T, Meera N, Binny K, Sekhar MS, Kishore G, Sasidharan S. Medication adherence and associated barriers in hypertension management in India. *CVD Prev Cont*. 2011;6(1):9-13.
78. Pan J, Wu L, Wang H, Lei T, Hu B, Xue X et al. Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients. *Medicine (Baltimore)*. 2019;98(27):1-13.
79. Park J-H, Shin Y, Lee S-Y, Lee SI. Antihypertensive drug medication adherence and its affecting factors in South Korea. *Int J Cardiol*. 2008;128(3):392-8.
80. Ishida T, Oh A, Hiroi S, Shimasaki Y, Nishigaki N, Tsuchihashi T. Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database. *Hypertens Res*. 2019;42(2):249.
81. Pinprapapan E, Panuthai S, Vannarit T, Srisuphan W. Casual model of adherence to therapeutic regimens among Thais with hypertension. *Pac Rim Int J Nurs Res*. 2013;17(3):268-81.
82. Goussous LS, Halasah NA, Halasa M. Non-Compliance to Antihypertensive Treatment among Patients Attending Prince Zaid Military Hospital. *World Family Medicine Journal: Incorporating the Middle East Journal of Family Medicine*. 2015;99(1645):1-5.
83. Organization WH. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013: World Health Organization2013.
84. Boucquemont J, Pai AL, Dharnidharka VR, Hebert D, Furth SL, Foster BJ. Gender differences in medication adherence among adolescent and young adult kidney transplant recipients. *Transplantation*. 2019;103(4):798-806.
85. Kumar K, Greenfield S, Raza K, Gill P, Stack R. Understanding adherence-related beliefs about medicine amongst patients of South Asian origin with diabetes and cardiovascular disease patients: a qualitative synthesis. *BMC Endocr Disord*. 2016;16(1):24-9.

86. Ens TA, Seneviratne CC, Jones C, Green TL, King-Shier KM. South Asians' cardiac medication adherence. *Eur J Cardiovasc*. 2014;13(4):357-68.
87. Hsu Y-H, Mao C-L, Wey M. Antihypertensive medication adherence among elderly Chinese Americans. *J Transcult Nurs*. 2010;21(4):297-305.
88. Garavalia L, Garavalia B, Spertus JA, Decker C. *J Cardiovasc Nurs*. 2009;24(5):371-9.
89. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Google Scholar. 2016.
90. Choudhry NK, Denberg TD, Qaseem A. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. *Ann Intern Med*. 2016;164(1):41-9.
91. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. *Arch Intern Med*. 2007;167(6):540-9.
92. Gazmararian JA, Williams MV, Peel J, Baker DW. Health literacy and knowledge of chronic disease. *Patient Educ Couns*. 2003;51(3):267-75.
93. Gwadry-Sridhar FH, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. *Value Health*. 2013;16(5):863-71.
94. Conn VS, Ruppar TM, Chase J-AD, Enriquez M, Cooper PS. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. *Curr Hypertens Rep*. 2015;17(12):94-109.
95. Palacio AM, Uribe C, Hazel-Fernandez L, Li H, Tamariz LJ, Garay SD et al. Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial. *J Gen Intern Med*. 2015;30(4):469-75.
96. Zomahoun HTV, Guenette L, Gregoire J-P, Lauzier S, Lawani AM, Ferdynus C et al. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. *Int J Epidemiol*. 2017;46(2):589-602.
97. Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR. The effect of reminder systems on patients' adherence to treatment. *Patient Prefer Adherence*. 2012;2012(6):127-35.
98. Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: A review from the patient's perspective. *Ther Clin Risk Manag*. 2008;4(1):269-86.